Meeting the iron requirements of infants and children is difficult, and supplementation or fortification of food with iron is often recommended. Although iron supplementation of infants and children with iron deficiency and iron-deficiency anemia may be beneficial, recent studies suggest that this may not be the case for those with adequate iron status, and adverse effects have been noted. The recent discoveries of proteins and peptides regulating iron absorption have enhanced our knowledge of iron metabolism in infants and children. Iron is taken up in the small intestine by divalent metal transporter-1 and is either stored by ferritin inside the mucosal cell or transported to the systemic circulation by ferroportin, while being oxidized by hephaestin to be incorporated into transferrin. Hepcidin, a small peptide synthesized by the liver, can sense iron stores and regulates iron transport by inhibition of ferroportin. However, regulation of iron transporters is immature in infants, possibly explaining the adverse effects of iron supplementation. Interactions among iron, vitamin A, zinc, and copper need to be considered when evaluating the effects of iron supplementation on infants and children.
Iron requirements
The healthy infant at term is born with iron stores that in part can be mobilized and utilized for growth during early infancy. In addition to these stores, the high levels of hemoglobin at birth will decrease and the iron will be recycled and also used for growth and blood-volume expansion. It is therefore frequently assumed that term infants need no or very little dietary iron to meet their requirements during early life. That breastmilk contains very little iron and breastfed infants rarely become iron deficient before 6 months of life are often used as arguments in support of this notion. However, there have been several studies in affluent populations showing that iron deficiency is common in this age group among infants fed formula unfortified with iron, in spite of the fact that such formula contains three to four times as much iron as breastmilk. Thus, it is obvious that infants do need a certain amount of bioavailable dietary iron during this period of life.
There have been theoretical approaches to estimate the iron requirements of infants. Total body iron varies with birthweight and has been estimated to be approximately 268 mg for an infant with a birthweight of 3.5 kg and approximately 183 mg for an infant with a birthweight of 2.5 kg [1, 2] . At 1 year of age, these values are 377 and 362 mg, respectively, and the amount of absorbed iron needed per day in these infants has been calculated as 0.55 and 0.75 mg, respectively, after taking iron losses into account [1] . Since the exclusively breastfed infant ingests about 0.16 to 0.24 mg of iron per day during the first 6 months and absorbs approximately 0.05 to 0.07 mg, and rarely becomes iron deficient, it is very obvious that these estimates have a poor correlation with true needs. It should be recognized that values for total body iron of infants must be viewed with caution: they were often derived from a very limited number of deceased infants quite some time ago, analytical techniques were of limited precision, and the cause of death was often uncertain. Further, it has recently been shown that daily losses (stool) have been grossly overestimated. This approach to estimating iron requirements therefore has very limited validity.
The adequate intake (AI) of iron for 0-to 6-monthold infants has been estimated as 0.27 mg/day, largely Bo Lönnerdal and Shannon L. Kelleher based on the iron intake of exclusively breastfed infants. It should be noted, though, that iron in breastmilk is well absorbed and infants fed formula absorb considerably less iron [3] . We have used another approach and "titrated" the iron requirement of formula-fed infants by feeding cow's milk formulas with different levels of iron exclusively from 4 to 6 weeks to 6 months of age [4, 5] . From these studies it was evident that feeding infant formula with an iron content of 1.6 mg/L resulted in similar iron status as feeding formulas with 2, 4, 7, or 12 mg/L. Thus, an iron intake of 1.3 to 1.6 mg/day appears to meet the iron requirement of 0-to 6-month-old, term, healthy, formula-fed infants. Earlier studies on infants fed unfortified formula, which at that time contained 0.8 to 1.0 mg of iron/L, showed iron deficiency, suggesting that iron intakes of 0.8 to 1.0 mg/day are inadequate for infants not being breastfed. It is obvious that low-birthweight infants, infants with frequent infections, and infants fed solid foods at a very young age would have a substantially higher daily need for iron, but their requirements are difficult to assess. Such infants, though, frequently become iron deficient and anemic by 6 months of age.
The recommended daily allowance (RDA) for infants 7 to 12 months of age is set at 11 mg/day. This is substantially higher than the estimates for younger infants and is based on the facts that iron stores are depleted by this age, growth is rapid, and the bioavailability of iron from most foods consumed at this age is low. The precise requirements for absorbed iron are difficult to estimate, but it is obvious that infants in this age group frequently become iron deficient and anemic [6] . Thus, there is a need for improved complementary foods, in most cases including iron fortification, and iron supplementation is often advocated (see below).
Absorption of iron
Iron homeostasis is primarily controlled through tightly regulated changes in iron absorption in adults. Three "regulators" of iron homeostasis mechanisms have been identified that are referred to as the "erythropoietic regulator, " the "stores regulator, " and the "dietary regulator" [7] . Regulation of these compartments is integrated to control iron absorption, protecting against both iron deficiency and overload, and may reflect a hierarchical response in the maintenance of iron homeostasis such that the erythropoietic regulator may be of primary importance only in response to chronic iron-deficiency anemia, while the stores regulator may play the predominant role in maintaining iron homeostasis in response to endogenous iron stores, and the dietary regulator may functionally respond to acute changes in iron intake, primarily to prevent iron overload. Although there is a large body of evidence concerning the integration of these three regulators in adults, we are just beginning to understand the integration of these mechanisms during infancy and childhood.
As mentioned previously, hemoglobin levels at birth are normally quite high and primarily consist of fetal hemoglobin (hemoglobin F or α 2 γ 2 ), which comprises 80% to 90% of the total hemoglobin synthesized, gradually decreasing to < 1% by 10 months of age in normal infants [8] . The switch from hemoglobin F to adult hemoglobin (hemoglobin A or α 2 β 2 ) begins around 12 weeks of gestation, although production of hemoglobin A occurs in the bone marrow where it remains throughout life [9] . Erythropoiesis almost ceases shortly after birth, resulting in a progressive fall in hemoglobin level that continues during the first 1 to 2 months of life [10] and providing an endogenous iron source for the growing neonate, during which time iron absorption is relatively low [11] . As the main component of the "erythropoietic regulator, " erythropoietin secretion from the kidney increases the erythropoietic drive [12] and results in increased iron absorption, facilitating the transition from "physiological anemia" toward considerable expansion of hemoglobin mass to meet the demands for rapid infant growth. During this transition, which occurs during mid-infancy, iron absorption increases from approximately 21% at 1 to 3 months to approximately 37% at 4 to 6 months [11, 13] as iron stores become depleted.
Although it would be expected that iron absorption is primarily regulated by and inversely related to iron stores, as it is in adults, many studies have shown that this may not be the case during infancy. For example, premature infants are born with lower endogenous iron stores in the liver and in hemoglobin than term infants [14] ; however, mean iron retention is similar (approximately 30%) [11, 13] , illustrating the inability of infants to appropriately compensate for low iron stores, and perhaps being more reflective of the high erythropoietic drive that normally occurs during this time. Moreover, Domellöf et al. [7] conducted a randomized, double-blind, placebo-controlled study in healthy, term infants who were iron supplemented (1 mg/kg/day) from 4 to 9 months of age (early initiation) or from 6 to 9 months of age (late initiation) and compared them with infants receiving placebo. At 6 months of age, iron absorption was independent of iron intake and iron status [7] , unlike observations in adults. By 9 months of age, though, iron absorption was correlated with recent dietary iron intake, as has been observed in adults, which is speculated to result from so-called mucosal block reflecting "dietary regulation" [15] . However, iron absorption was not yet correlated with iron status. Furthermore, in young infants (4 to 6 months), but not older infants (6 to 9 months), iron supplementation increased hemoglobin concentration regardless of iron status, suggesting that changes in the normal erythropoietic drive that occur during this time play a major role in iron metabolism during early but not late infancy [16] . Similarly, a study on Peruvian infants between 6 and 9 months of age showed that iron absorption was similar in anemic and nonanemic infants [17] ; however, in this population iron absorption was significantly inversely correlated with iron stores (serum ferritin). Although the discrepancy between these two studies is currently not understood, taken together these observations suggest that unlike in adults, iron absorption during early infancy may be primarily regulated by developmental changes in erythropoietic drive, secondarily by dietary intake, and least sensitively by endogenous iron stores and suggest that infants may develop the ability to regulate iron absorption postnatally; however, the question remains as to how and when this developmental switch from endogenous iron mobilization to dietary iron absorption occurs.
Mechanisms regulating iron absorption
Iron homeostasis is regulated at the level of intestinal absorption, and as more contributors to the iron transport process are identified and characterized, the complexity of iron homeostasis becomes increasingly evident. A number of proteins must coordinate the transfer of iron across the enterocyte and into the systemic circulation. Dietary iron generally occurs in the ferric (Fe +3 ) state and thus must be reduced to the ferrous form (Fe +2 ) prior to uptake into the enterocyte, presumably by an apical membrane-associated ferric reductase, probably duodenal cytochrome b (Dcytb) [18] , facilitating ferrous iron uptake across the apical membrane into the enterocyte via divalent metal transporter-1 (DMT1) [19] . Once inside the cell, iron may partition into specific cellular pools or may be transported across the basolateral membrane into the systemic circulation via ferroportin-1 (FPN1)/ironregulated transporter 1 (IREG1)/metal transporter protein-1 (MTP1)/SLC40A1 [20] . Iron transfer from the enterocyte into the systemic circulation requires the oxidation of Fe +2 to Fe +3 , which is facilitated by hephaestin, a copper-containing ferroxidase homologous to ceruloplasmin that is associated with the basolateral membrane [21] , thus allowing ferric iron to be incorporated into apo-transferrin in the circulation. As in most mammalian cells, transferrin receptor is localized to the basolateral membrane of the enterocyte, and in combination with the hemochromatosis protein (HFE) permits the successful binding of transferrin-bound iron and reuptake back into the intestinal cell [22] . However, the role enterocytic transferrin receptor/HFE plays in the regulation of intestinal iron absorption is not well understood. Recently, hepcidin, an antimicrobial peptide produced by the liver, has been shown to modulate enterocyte iron transport, and it is believed to be the communication link or "stores regulator" between endogenous liver iron stores and intestinal iron uptake, facilitating increased iron absorption during iron deficiency and decreased iron absorption during iron repletion [23] in adults (see below). Hepcidin levels parallel liver iron stores in adults, and recent evidence indicates that hepcidin binds to FPN1, stimulates FPN1 internalization and degradation, and thus reduces iron absorption when liver iron stores are high [24] . However, the regulation of this process in infants is not understood.
Ontogeny of iron transport mechanisms in the small intestine
The maturation of iron homeostasis from erythropoietic→dietary→stores regulation in infants to stores→dietary→erythropoietic regulation in adults suggests the existence of postnatal ontogenic changes. Iron homeostasis is primarily regulated at the level of intestinal absorption in adults; thus, the ontogeny of this homeostatic system has developmental consequences. Similar to observations in human infants [11, 13] , we have detected an age-related increase in iron absorption using a suckling rat pup model (day 5, 41 ± 13%; day 10, 60 ± 8%; day 20, 79 ± 8%), which is associated with a concurrent decline in iron retention in the small intestine (day 5, 25 ± 7%; day 10, 19 ± 2%; day 20, 6 ± 2%) (unpublished data). This observation has led us to speculate that the increase in iron absorption that occurs during infancy reflects the maturation of small intestine iron absorption mechanisms to facilitate iron transfer into the systemic circulation. However, the precise mechanisms that are responsible for the postnatal ontogeny of iron absorption are not well understood. Since mechanistic studies cannot be conducted in human infants because of ethical considerations, we have validated the use of the suckling rat pup as a model of ontogenic changes that occur postnatally. Observations from these studies indicate that the postnatal increase in iron absorption results from multifactorial regulation that includes increased expression of DMT1, FPN1, and hephaestin and changes in the localization of these transport proteins within the enterocyte itself [25] . For example, during mid-infancy, both DMT1 and FPN1 are localized within the enterocyte, whereas during weaning, DMT1 and FPN1 are localized appropriately at the apical and basolateral membranes, respectively. This indicates that at least several of the main regulators of intestinal iron absorption may not be localized appropriately until late infancy, which would limit the ability to homeostatically control iron absorption until this age.
Iron metabolism
In adults, absorbed iron is transported to the liver by transferrin, where it is taken up into hepatocytes by transferrin receptors and stored sequestered in ferritin until needed. During times of high iron demand, iron is released from ferritin and mobilized into the hepatic circulation for further distribution to the tissues. The regulation of this process is just beginning to be elucidated, and our understanding has been aided by the identification of several genes expressed in the liver that when mutated cause hereditary hemochromatosis, resulting in iron overload. These genes include those for hepcidin, HFE, transferrin receptor 2 (TfR2), and hemojuvelin.
Hepcidin is a small peptide (25 amino acids) that was first identified as an antimicrobial peptide in urine and plasma [26] . It was subsequently discovered to have a profound role in the regulation of iron metabolism, since mice with dietary iron overload were found to have substantially increased hepcidin mRNA expression and decreased iron absorption [23] , providing evidence that hepcidin is involved in iron homeostasis. Hepcidin knockout mice showed a hemochromatosislike phenotype, further establishing hepcidin as a negative regulator of iron absorption. Several factors regulating iron absorption, such as iron stores, erythropoiesis, inflammation, and hypoxia, have also been found to regulate liver expression of hepcidin. Thus, intestinal iron absorption is inversely correlated with hepcidin expression.
The discovery of hepcidin also provided evidence against the hypothesis that signals from the body to alter iron metabolism were detected by intestinal crypt cells and programmed them to absorb more or less iron when they matured. Recent results in animals show that injection of hepcidin reduces serum iron within 4 hours, demonstrating that hepcidin modulates iron absorption very quickly [27] . It is evident that liver hepcidin expression is a key regulator of iron metabolism. The most common form of hereditary hemochromatosis involves mutations in HFE, a protein highly expressed in liver, which leads to inappropriately low levels of hepcidin [28] , inappropriately high iron absorption, and hepatic iron overload. TfR2 is also highly expressed in liver, and mutations in this protein cause iron loading disease with symptoms very similar to those observed in hemochromatosis due to defective HFE [29] . Hepcidin levels are very low in these patients, suggesting that HFE and TfR2 are part of the same regulatory pathway. Recently, hemojuvelin, a third member of this regulatory network, was identified [30] . This protein is expressed in hepatocytes and is mutated in most cases of juvenile hemochromatosis. These patients suffer from rapid iron overload, which is much more severe than in patients with defective HFE or TfR2, and they have undetectable levels of hepcidin. How these three molecules sense body iron requirements and regulate hepcidin expression is not yet known. However, this mechanism must be able to sense events occurring at distant sites in the body, such as changes in iron requirements of developing erythroid cells in the marrow. Recent studies show a close correlation between levels of diferric transferrin and liver hepcidin expression, suggesting that the iron saturation of transferrin, which is affected by iron needs, may be the key messenger from the tissues and the marrow to the hepatocyte [31] . This is corroborated by the observation that hemoglobin-deficit (hbd) mice, which have an inherited anemia, have inordinately high levels of hepcidin, whereas anemic control mice have very low levels of hepcidin [32] . The hbd mice have very high levels of diferric transferrin (because their hemoglobin production is defective), which would up-regulate hepcidin expression. Further studies on the role of transferrin saturation in the regulation of iron metabolism are now needed.
The anemia of chronic disease is commonly associated with infections and inflammatory conditions. In this anemia, macrophages retain iron, and iron absorption is decreased, resulting in hypoferremia. It has recently been shown that interleukin-6 and lipopolysaccharide increase hepcidin expression [29] , providing a mechanistic explanation for these observations.
Iron supplementation
Iron supplementation has been shown to be effective in treating and preventing iron deficiency. The iron is provided in ferrous form with ascorbic acid, usually at a dose of 1 mg/kg/day. The current recommendation is to start the supplements after 6 months of age, on the assumption that the iron endowment at birth, combined with iron from breastmilk or alternative food sources, will be sufficient to meet iron requirements up to this age. It is apparent, however, that many infants in less-developed countries become iron deficient before 6 months of age. This could be due to lower than normal iron stores at birth, which may be caused by maternal iron deficiency during pregnancy, low birthweight or prematurity, frequent infections, or early introduction of solid foods with low iron content and/or low iron bioavailability. Introduction of iron at an earlier age than 6 months might therefore be considered. As mentioned previously, this hypothesis was tested in a double-blind, randomized, controlled trial performed at two study sites (Sweden and Honduras) representing infants with very varying iron status at the start of the study [16] . Breastfed infants were given either iron supplements (1 mg/kg/day) or placebo from 4 or 6 months until 9 months of age. The infants were exclusively breastfed until 6 months of age and predominantly breastfed until 9 months of age. Iron intake from complementary foods was assessed by dietary records and food-composition tables. Iron supplementation between 4 and 6 months of age increased hemoglobin and serum ferritin to a similar extent in both Honduran and Swedish infants, regardless of the fact that the Swedish infants had adequate iron status at 4 months of age. Between 6 and 9 months, the effect of iron supplementation was similar in both populations, except for hemoglobin, which increased only in the Honduran infants, and reduced anemia from 29% to 9%. There were no significant differences in iron status indicators between groups that received iron from 4 or 6 months of age. The unexpected increase in hemoglobin between 4 and 6 months of age in an iron-replete population suggested that homeostatic regulation of iron metabolism is immature at this age.
Iron absorption studies at 6 and 9 months of age using stable isotopes showed that there was no significant difference in iron absorption at 6 months between Swedish infants who had received iron supplements and those given placebo [7] . At 9 months, however, infants who had been supplemented with iron absorbed 17% of iron from breastmilk, whereas unsupplemented infants absorbed 37% of the dose. Thus, homeostatic regulation of iron absorption occurred at 9 months, but not at 6 months of age, suggesting that regulatory mechanisms are immature at a young age. Studies in rat pups support these observations and provide a potential mechanistic explanation. Nursing rat pups were supplemented daily with iron (at a dose proportional to that given to human infants) or placebo from birth to weaning. At day 10 ("young infants") and day 20 ("older infants"), iron absorption was assessed with the use of radioisotopes [33] . The animals were killed at day 10 or 20, and tissue levels of iron and the expression of iron transporters were assessed. In a parallel study, dams were fed an iron-deficient diet during pregnancy and the iron-deficient rat pups were supplemented with iron or placebo from birth to weaning [34] . At day 10, there was no difference between the groups in iron absorption, whereas at day 20, irondeficient pups absorbed more iron than those fed placebo, and those supplemented with iron absorbed less iron. Thus, these findings are in agreement with the observations in human infants at 6 and 9 months. At day 10, there was no effect of iron status on the iron transporters DMT1 and FPN1. At day 20, however, iron-supplemented pups had significantly lower levels and iron-deficient pups had significantly higher levels of the iron transporters than pups given placebo. Thus, it appears that homeostatic up-and down-regulation of the intestinal iron transporters is immature at a young age. Hepcidin expression responded to body iron stores even during early infancy, when DMT1 and FPN1 were unresponsive, suggesting that it is not the signal from iron stores ("stores regulator") that is immature [35] . At birth, hepcidin expression was exceptionally high and then declined to very low levels by day 10, which may explain the low iron absorption of young infants.
Although iron supplements had beneficial effects, in that they were shown to reduce anemia in Honduran infants between 6 and 9 months of age, some adverse effects were also noted in this study [36] . Among Swedish infants, gains in length and head circumference were significantly lower in those who received iron than in those given placebo from 4 to 9 months. The same effect on length was observed in Honduras, but only between 4 and 6 months among those with hemoglobin ≥ 110 g/L. Among infants with hemoglobin < 110 g/L at 4 months, diarrhea was less common in those given iron than in those given placebo from 4 to 9 months, whereas the opposite was true among those with hemoglobin ≥ 110 g/L. Further, we found that infants supplemented with iron had significantly lower copper status (assessed by erythrocyte copper/zinc-superoxide dismutase [CuZn-SOD] activity) at 9 months of age than those receiving placebo [37] . Thus, routine iron supplementation of infants may benefit those with low hemoglobin but may present risks for those with normal hemoglobin. These findings are consistent with those of a study by Idjradinata et al. [38] , who found that weight gain in iron-replete Indonesian children (12 to 18 months old) was significantly lower in those given iron (3 mg/kg/day) for 4 months than in those given placebo. The growth of iron-deficient, anemic children was improved by iron supplementation, whereas irondeficient, nonanemic children were unaffected. To date, few studies have reported such adverse effects, but it should be noted that very few studies on infants and children have separated their populations into initially iron-deficient and iron-replete subjects. It is not yet known why these adverse effects were observed in iron-replete infants and children. It is possible that iron itself causes toxic effects when absorbed in excess, possibly through free radical-mediated reactions. It is also possible that iron interferes with zinc metabolism and that the adverse effects are due to local or systemic suboptimal zinc status, which in turn can affect growth via the insulin-like growth factor-1/ growth hormone (IGF-1/GH) axis and morbidity via impaired immune function. Further studies are needed to resolve this question.
Iron fortification of foods for infants and children has not been found to have any adverse effects on growth or morbidity. It is possible that the lower amount of iron absorbed from each fortified meal is less likely to cause such effects than the larger amount absorbed from an iron supplement that is usually given to infants and children in a "semifasting" state. It is also possible that iron introduced in "free form" (as a supplement) affects iron metabolism in a different manner than iron given as a fortificant. A recent study on Swedish infants between 6 and 9 months of age showed that iron given as drops resulted in a significant increase in iron stores (measured by serum ferritin), whereas the same amount of iron given in fortified cereal had no effect [39] . In contrast, iron fortification resulted in a significant increase in infant hemoglobin at 9 months, whereas iron supplements did not. Thus, different forms of iron appear to be metabolized differently, possibly mediated via hepcidin affecting iron transporters in the intestine and the reticuloendothelial system.
Interactions between other micronutrients and iron metabolism
Many iron-supplementation programs targeted at infants have been implemented throughout the world, including in developed countries, and it is common pediatric practice in the United States to prescribe ferrous sulfate drops to all infants through the first year of life. The failure of iron supplementation to cure anemia, which is commonly observed, is often ascribed to poor compliance or an inadequate duration of supplementation. However, quite often multiple micronutrient deficiencies coexist [40] , and interactions between iron metabolism and other micronutrients have been detected, all of which may play a role in these observations.
Vitamin A
Vitamin A deficiency is associated with secondary iron-deficiency anemia, and many studies have shown a positive effect of vitamin A supplementation on iron status in humans and in animal models [41, 42] . Vitamin A deficiency reduces the incorporation of iron into erythrocytes [43] , alters red blood cell morphology [44] , produces mild anemia [45] , lowers plasma total iron-binding capacity, increases iron absorption, and causes accumulation of iron in the spleen and bone [46] . The relatively high prevalence of marginal vitamin A status among pregnant and lactating women has raised concern about its contribution to morbidity and mortality and its contribution to the etiology of anemia among women and their infants [41] . Interestingly, Schmidt et al. observed a positive effect of improved vitamin A status during pregnancy on maternal and infant iron status [47] and a trend toward increased milk iron concentration, which was lower in women supplemented with iron alone than in women supplemented with iron and vitamin A, suggesting a positive effect of improved vitamin A status on mammary gland iron metabolism. Using a lactating rat model, we have previously determined specific effects of a marginal vitamin A diet on iron transporters in the mammary gland and liver and found that liver transferrin receptor expression was higher while mammary gland transferrin receptor expression was lower in rats fed a marginal vitamin A diet, a result suggesting that vitamin A deficiency increases iron acquisition in the liver at the expense of the mammary gland. Furthermore, DMT1 and FPN1 protein levels in the liver and mammary gland were lower in rats fed a marginal vitamin A diet, indicating that there are tissue-specific responses to vitamin A deficiency and that a diet marginal in vitamin A results in specific effects on iron transporters. Some of these effects may be a consequence of retinoic acid decreasing [48] or increasing [49] transferrin receptor levels and thus altering tissue iron acquisition. Okano et al. [50] found that retinoic acid up-regulated erythropoietin production threefold in HepG2 cells and further found elevated serum erythropoietin concentrations in rats intragastrically injected with retinoic acid. However, a recent study in severely anemic preschoolers [51] indicated that vitamin A supplementation actually suppressed erythropoietin production but was associated with increased iron mobilization and erythropoiesis. Although the authors speculated that the reduced erythropoietin levels were a consequence of increased iron mobilization and erythropoiesis, these results illustrate our lack of understanding of the role vitamin A plays in regulating iron metabolism. There is little information regarding the effects of iron supplementation on vitamin A status; however, in a randomized, double-blind, placebo-controlled study of infants aged 4 months, Wieringa et al. [52] found that iron reduced plasma and increased liver retinol concentrations, suggesting a redistribution of retinol from plasma to the liver. In contrast, Jang et al. [53] showed that iron deficiency inhibited the mobilization of retinol stores in rats, which may impair the absorption and utilization of vitamin A in rats. This interaction warrants further investigation, as it may require caution when supplementing populations where vitamin A deficiency and iron deficiency are both common.
Zinc
Although zinc deficiency is estimated to affect approximately 20% of the world's population [54] , there is little evidence to suggest that zinc deficiency affects iron metabolism. In contrast, adverse effects of zinc supplementation on iron metabolism have been demonstrated, such as decreased iron absorption, hemoglobin, and serum ferritin levels in adults [55] [56] [57] [58] . Although no direct effect of zinc supplementation on iron status in infants older than 6 months in developing countries has been observed [59] , we previously determined that young infant rhesus monkeys supplemented with zinc (approximately 7.5 mg/day) from birth to 4 months had reduced iron absorption and impaired iron status [60] . With that said, several studies have observed a negative effect of zinc on recovery from anemia [61] , hemoglobin repletion [62] , and ferritin concentration [55] . Using our suckling rat model, we determined that zinc supplementation negatively affects iron absorption in an age-dependent manner in such a way that during early infancy zinc supplementation was associated with increased small intestine iron retention, decreased hephaestin, and increased FPN1 expression in the small intestine [25] . In contrast, during late infancy, when DMT1 and FPN1 are appropriately localized to the apical and basolateral membranes, respectively, the negative effects of zinc supplementation on iron absorption were absent. Although the precise mechanisms by which these effects are mediated are not understood, zinc treatment increases DMT1 and FPN1 expression in enterocyte-like Caco-2 cells [63] , indicating specific effects of zinc supplementation on intestinal iron transporters.
Few studies have observed negative effects of iron supplementation on zinc metabolism. For example, Yip et al. [64] randomized 1-year-old infants to receive 30 mg of iron/day or placebo and after 3 months of supplementation, found no significant difference in serum zinc concentration between the groups. Another small study (N = 11) found no effect on zinc absorption with the addition of iron (5 mg/serving) to a commercial vegetable-based weaning food among 9-month old infants [65] . However, in a study of Honduran children, we observed an increase in the incidence of morbidity in infants who received iron supplements, and iron supplementation also resulted in a negative effect on growth [36] . An enhancing effect of iron on bacterial growth has been demonstrated both in vitro and in vivo [66, 67] , whereas the negative effect on infant growth suggests that iron supplementation may indirectly affect the IGF-1/GH axis through interference with zinc absorption in the intestine.
Copper
Changes in copper status may alter iron homeostasis so that copper deficiency results in iron-deficiency anemia and accumulation of iron in the small intestine, liver, and spleen. Recent evidence in mice suggests that this may be a consequence of decreased expression of hephaestin in the small intestine and hepcidin in the liver [68] . However, copper deficiency and excess are not common in humans; thus, the relevance of these observations to human health is not known. In contrast, a number of reports indicate that iron status affects copper metabolism. For example, serum copper level was higher in children (1 to 14 years old) with iron-deficiency anemia [69] than in healthy controls. Furthermore, Domellöf et al. [37] observed higher plasma copper and erythrocyte CuZn-SOD activity (both markers of copper status) in Honduran infants than in Swedish infants at 9 months of age, suggesting that poor iron status affects copper metabolism. Moreover, several studies have shown that iron supplementation or iron fortification in infants may reduce copper absorption [70] and compromise copper status [5] . For example, studies conducted in iron-supplemented infants and young children have documented significantly lower CuZn-SOD activity [37, 71] and decreased ceruloplasmin activity and serum copper levels [72] , suggesting that copper metabolism is impaired. Although it is currently unknown whether the mechanism behind this interaction is a direct or indirect effect of iron on copper metabolism, observations such as these indicate that care should be taken when implementing iron-supplementation programs in infants.
